Selecta Biosciences Inc (NASDAQ:SELB) has earned an average broker rating score of 1.33 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company.

Analysts have set a 1-year consensus target price of $23.67 for the company and are predicting that the company will post ($0.48) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Selecta Biosciences an industry rank of 92 out of 265 based on the ratings given to its competitors.

SELB has been the topic of several recent analyst reports. Needham & Company LLC started coverage on Selecta Biosciences in a research note on Monday, July 18th. They set a “buy” rating and a $28.00 price objective on the stock. Canaccord Genuity started coverage on Selecta Biosciences in a research report on Monday, July 18th. They set a “buy” rating and a $20.00 target price for the company. Finally, Stifel Nicolaus started coverage on Selecta Biosciences in a research report on Monday, July 18th. They set a “buy” rating and a $23.00 target price for the company.

In other news, Director Amir Nashat acquired 150,000 shares of the firm’s stock in a transaction that occurred on Monday, June 27th. The stock was bought at an average price of $14.00 per share, with a total value of $2,100,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Nanodimension Management Ltd acquired 385,000 shares of the firm’s stock in a transaction that occurred on Monday, June 27th. The stock was purchased at an average cost of $14.00 per share, with a total value of $5,390,000.00. The disclosure for this purchase can be found here.

Large investors have recently made changes to their positions in the company. Monashee Investment Management LLC purchased a new stake in shares of Selecta Biosciences during the second quarter valued at $350,000. Laurion Capital Management LP purchased a new stake in shares of Selecta Biosciences during the second quarter valued at $350,000. Marshall Wace LLP purchased a new stake in shares of Selecta Biosciences during the second quarter valued at $506,000. Vanguard Group Inc. purchased a new stake in shares of Selecta Biosciences during the second quarter valued at $1,679,000. Finally, FMR LLC purchased a new stake in shares of Selecta Biosciences during the second quarter valued at $3,997,000.

Selecta Biosciences (NASDAQ:SELB) traded up 2.99% during midday trading on Monday, reaching $13.42. 10,410 shares of the company traded hands. The firm has a 50-day moving average price of $12.13 and a 200-day moving average price of $12.87. Selecta Biosciences has a one year low of $10.26 and a one year high of $16.32.

About Selecta Biosciences

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.

5 Day Chart for NASDAQ:SELB

Get a free copy of the Zacks research report on Selecta Biosciences (SELB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Selecta Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.